SEEL

Seelos Therapeutics (SEEL)

Seelos Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:SEEL

<< 前へ 1 2 3 4 5 6 7 8 9 10 11 12 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2020/11/14	06 : 18	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:SEEL	Seelos Therapeutics Inc
2020/11/13	06 : 40	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:SEEL	Seelos Therapeutics Inc
2020/11/09	23 : 24	PR Newswire (US)	Seelos Therapeutics to Participate in the 3rd International Conference on Sanfilippo Syndrome and Related Diseases	NASDAQ:SEEL	Seelos Therapeutics Inc
2020/10/26	22 : 00	PR Newswire (US)	Seelos Therapeutics Announces Issuance of Composition of Matter Patent for SLS-007	NASDAQ:SEEL	Seelos Therapeutics Inc
2020/10/22	22 : 00	PR Newswire (US)	Seelos Therapeutics to Participate in Investor Conferences in November	NASDAQ:SEEL	Seelos Therapeutics Inc
2020/09/23	22 : 00	PR Newswire (US)	Seelos Therapeutics Announces Sponsored Research Agreement with Duke University for Gene Therapy Studies of SLS-004 in Parkin...	NASDAQ:SEEL	Seelos Therapeutics Inc
2020/09/15	05 : 03	Edgar (US Regulatory)	Small Company Offering and Sale of Securities Without Registration (d)	NASDAQ:SEEL	Seelos Therapeutics Inc
2020/09/14	22 : 00	PR Newswire (US)	Seelos Announces Issuance of a New Patent and an Additional Notice of Allowance in Japan for Intranasal Racemic Ketamine (SLS...	NASDAQ:SEEL	Seelos Therapeutics Inc
2020/09/10	22 : 00	PR Newswire (US)	Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005)	NASDAQ:SEEL	Seelos Therapeutics Inc
2020/09/10	05 : 03	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:SEEL	Seelos Therapeutics Inc
2020/09/10	03 : 00	PR Newswire (US)	Seelos Therapeutics Announces Closing of $7.0 Million Registered Direct Offering	NASDAQ:SEEL	Seelos Therapeutics Inc
2020/09/09	05 : 44	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)	NASDAQ:SEEL	Seelos Therapeutics Inc
2020/09/04	22 : 08	PR Newswire (US)	Seelos Therapeutics Announces Pricing of $7.0 Million Registered Direct Offering	NASDAQ:SEEL	Seelos Therapeutics Inc
2020/08/28	21 : 00	PR Newswire (US)	Seelos Therapeutics to Participate in the Cantor Virtual Global Healthcare Conference	NASDAQ:SEEL	Seelos Therapeutics Inc
2020/08/26	00 : 00	PR Newswire (US)	Seelos Therapeutics Receives European Orphan Drug Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome	NASDAQ:SEEL	Seelos Therapeutics Inc
2020/08/10	22 : 15	PR Newswire (US)	Seelos Therapeutics Receives FDA May Proceed Notice to Initiate a Phase IIb/III Trial of SLS-005 in Amyotrophic Lateral Scler...	NASDAQ:SEEL	Seelos Therapeutics Inc
2020/07/21	22 : 00	PR Newswire (US)	Seelos Therapeutics Receives Positive EMA Opinion on Orphan Drug Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome	NASDAQ:SEEL	Seelos Therapeutics Inc
2020/07/17	05 : 31	PR Newswire (US)	Seelos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:SEEL	Seelos Therapeutics Inc
2020/07/17	05 : 30	PR Newswire (US)	Seelos Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:SEEL	Seelos Therapeutics Inc
2020/06/25	21 : 00	PR Newswire (US)	Seelos Therapeutics Announces Initiation of Preclinical Study of SLS-007 in Parkinson's Disease	NASDAQ:SEEL	Seelos Therapeutics Inc
2020/06/23	20 : 00	GlobeNewswire Inc.	Seelos Therapeutics Announces Final Data from Phase I PK/PD Study of Intranasal Racemic Ketamine (SLS-002) and Clinical Devel...	NASDAQ:SEEL	Seelos Therapeutics Inc
2020/06/15	21 : 01	GlobeNewswire Inc.	Seelos Therapeutics to Host Key Opinion Leader Call to Discuss Phase I Data and Upcoming Trial Design for SLS-002	NASDAQ:SEEL	Seelos Therapeutics Inc
2020/06/13	05 : 16	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:SEEL	Seelos Therapeutics Inc
2020/06/11	22 : 01	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:SEEL	Seelos Therapeutics Inc
2020/05/28	20 : 01	GlobeNewswire Inc.	Seelos Therapeutics Announces Initiation of Preclinical Study of SLS-004 in Parkinson’s Disease	NASDAQ:SEEL	Seelos Therapeutics Inc
2020/05/22	05 : 17	Edgar (US Regulatory)	Securities Registration: Employee Benefit Plan (s-8)	NASDAQ:SEEL	Seelos Therapeutics Inc
2020/05/21	19 : 02	Edgar (US Regulatory)	Amended Current Report Filing (8-k/a)	NASDAQ:SEEL	Seelos Therapeutics Inc
2020/05/19	22 : 01	GlobeNewswire Inc.	Seelos Therapeutics to Host Key Opinion Leader Call to Discuss the Unmet Medical Needs in Suicide and Depression	NASDAQ:SEEL	Seelos Therapeutics Inc
2020/05/19	21 : 31	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:SEEL	Seelos Therapeutics Inc
2020/05/18	21 : 01	GlobeNewswire Inc.	Seelos Therapeutics to Participate in the Benchmark Healthcare Virtual Conference	NASDAQ:SEEL	Seelos Therapeutics Inc